Nabota
Overview
Nabota (나보타) is a botulinum toxin type A preparation developed by Daewoong Pharmaceutical. Since receiving approval from the Ministry of Food and Drug Safety of South Korea in 2014, it has been widely used in cosmetic and therapeutic fields. Botulinum toxin works by inhibiting the release of acetylcholine at the neuromuscular junction, temporarily paralyzing muscles. This mechanism is utilized for various medical and cosmetic purposes, including wrinkle improvement, muscle spasm relief, and treatment of hyperhidrosis. Nabota is particularly characterized by maintaining a high-purity 900kDa complex during the purification process, enhancing its efficacy and safety. It has also obtained U.S. FDA approval, gaining recognition for its competitiveness in the global market.
Main Content
Development Background and History
Nabota is a botulinum toxin preparation that was first approved in South Korea in 2014 after more than 10 years of research and development by Daewoong Pharmaceutical. It was launched emphasizing cost competitiveness and safety compared to existing foreign products such as Botox (Allergan) and Dysport (Galderma). Subsequently, it obtained U.S. FDA approval in 2019, successfully entering the global market, and is currently exported to over 60 countries.
Mechanism of Action
The active ingredient of Nabota is botulinum toxin type A, which blocks the release of acetylcholine at nerve endings, inhibiting muscle contraction. This effect begins to appear within 1 to 3 days after injection, reaches maximum effect after 1 to 2 weeks, and typically lasts for 3 to 6 months. Over time, nerve endings regenerate and muscle function recovers, necessitating repeated procedures.
Indications
- Cosmetic purposes: Periorbital wrinkles (glabellar lines, forehead wrinkles, crow's feet), perioral wrinkles, masseter reduction (masseter hypertrophy), trapezius and calf muscle reduction, etc.
- Therapeutic purposes: Strabismus, blepharospasm, cervical dystonia, post-stroke upper limb spasticity, lower limb spasticity related to pediatric cerebral palsy, chronic migraine, hyperhidrosis (axillary, palmar), overactive bladder, etc.
Procedure and Precautions
Nabota is administered via intramuscular injection under a doctor's prescription. Caution is required in cases of allergic reactions, pregnancy or breastfeeding, or neuromuscular disorders (e.g., myasthenia gravis). Reported side effects may include injection site pain, swelling, bruising, and rarely, ptosis, asymmetry, or generalized muscle weakness.
Comparison with Competing Products
Nabota competes with Botox, Dysport, Xeomin, and Elavie. It particularly highlights advantages such as lower cost compared to Botox and a lower protein content, reducing the risk of antibody formation. Additionally, Daewoong Pharmaceutical emphasizes the high-purity toxin produced through its proprietary purification technology, ensuring efficacy and stability.
Latest Trends
As of 2024, Nabota is expanding its market share globally. In the U.S., it has shown steady growth in the cosmetic market since FDA approval, and it is pursuing entry into the Chinese market by 2025. Furthermore, Daewoong Pharmaceutical is conducting clinical trials to expand Nabota's indications, researching its potential application in new therapeutic areas such as chronic pain and depression. Recently, the company is also accelerating the development of a long-acting formulation that extends the duration of Nabota's effects. Meanwhile, in South Korea, regulations on the safety and adverse event reporting of botulinum toxin preparations have been strengthened, prompting manufacturers to focus more on quality control and transparency.
Related Topics
- [[Botulinum toxin]]
- [[Daewoong Pharmaceutical]]
- [[Cosmetic surgery]]
- [[Muscle spasm treatment]]
---
AI auto-generated document · Improved by the community